Insider Selling: Compugen (NASDAQ:CGEN) CEO Sells 5,000 Shares of Stock

Compugen Ltd. (NASDAQ:CGEN) CEO Eran Ophir sold 5,000 shares of the stock in a transaction on Tuesday, April 14th. The shares were sold at an average price of $2.90, for a total transaction of $14,500.00. Following the completion of the transaction, the chief executive officer owned 11,375 shares of the company’s stock, valued at approximately $32,987.50. This represents a 30.53% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Eran Ophir also recently made the following trade(s):

• On Wednesday, April 1st, Eran Ophir sold 5,625 shares of Compugen stock. The shares were sold at an average price of $2.21, for a total transaction of $12,431.25.

Compugen Stock Performance

Shares of CGEN stock traded up $0.01 during mid-day trading on Wednesday, reaching $2.89. The company’s stock had a trading volume of 671,759 shares, compared to its average volume of 395,055. Compugen Ltd. has a 1-year low of $1.23 and a 1-year high of $2.94. The company has a market cap of $273.25 million, a P/E ratio of 7.81 and a beta of 2.77. The firm’s 50-day moving average is $2.04 and its two-hundred day moving average is $1.83.

Compugen (NASDAQ:CGEN) last announced its quarterly earnings data on Monday, March 2nd. The biotechnology company reported $0.60 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.05 by $0.55. Compugen had a net margin of 48.57% and a return on equity of 55.68%. The company had revenue of $67.33 million during the quarter, compared to analysts’ expectations of $14.30 million. Sell-side analysts anticipate that Compugen Ltd. will post -0.03 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on CGEN. Lake Street Capital began coverage on shares of Compugen in a research report on Tuesday, April 7th. They set a “buy” rating and a $6.00 target price for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Compugen in a research report on Wednesday, January 21st. HC Wainwright began coverage on shares of Compugen in a research report on Wednesday, January 7th. They set a “buy” rating and a $4.00 target price for the company. Truist Financial upgraded shares of Compugen to a “strong-buy” rating in a research report on Wednesday, March 25th. Finally, Wall Street Zen upgraded shares of Compugen from a “hold” rating to a “buy” rating in a research report on Saturday, March 7th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Compugen has a consensus rating of “Moderate Buy” and a consensus price target of $5.00.

Institutional Investors Weigh In On Compugen

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CGEN. Bank Hapoalim BM acquired a new stake in Compugen in the 4th quarter valued at about $37,000. Security National Bank of Sioux City Iowa IA bought a new position in shares of Compugen in the 4th quarter valued at about $38,000. Franklin Resources Inc. bought a new position in shares of Compugen in the 2nd quarter valued at about $56,000. Osaic Holdings Inc. boosted its stake in shares of Compugen by 346.0% in the 2nd quarter. Osaic Holdings Inc. now owns 43,885 shares of the biotechnology company’s stock valued at $78,000 after purchasing an additional 34,045 shares during the last quarter. Finally, WINTON GROUP Ltd bought a new position in shares of Compugen in the 4th quarter valued at about $84,000. Institutional investors and hedge funds own 12.22% of the company’s stock.

Compugen Company Profile

Compugen Ltd. (NASDAQ: CGEN) is a clinical-stage therapeutic discovery company that leverages proprietary computational discovery platforms to identify novel immuno-oncology targets and biomarkers. The company combines large-scale biological datasets with machine learning algorithms to generate and validate new therapeutic and diagnostic candidates. Founded in 1993 and headquartered in Tel Aviv, Israel, Compugen also maintains a presence in the United States to support its clinical development and commercial collaborations.

Compugen’s predictive discovery engine scans complex biological systems in silico to reveal previously unrecognized pathways and immune checkpoints involved in cancer progression.